PL1729810T3 - Sposoby agregacji IL-1ra - Google Patents

Sposoby agregacji IL-1ra

Info

Publication number
PL1729810T3
PL1729810T3 PL05733155T PL05733155T PL1729810T3 PL 1729810 T3 PL1729810 T3 PL 1729810T3 PL 05733155 T PL05733155 T PL 05733155T PL 05733155 T PL05733155 T PL 05733155T PL 1729810 T3 PL1729810 T3 PL 1729810T3
Authority
PL
Poland
Prior art keywords
methods
reducing aggregation
aggregation
reducing
Prior art date
Application number
PL05733155T
Other languages
English (en)
Inventor
Andrei Raibekas
Bruce Kerwin
Original Assignee
Swedish Orphan Biovitrum Ab (Publ)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Swedish Orphan Biovitrum Ab (Publ) filed Critical Swedish Orphan Biovitrum Ab (Publ)
Publication of PL1729810T3 publication Critical patent/PL1729810T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/42—Phosphorus; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/545—IL-1
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL05733155T 2004-04-02 2005-04-01 Sposoby agregacji IL-1ra PL1729810T3 (pl)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US55916104P 2004-04-02 2004-04-02
US55887904P 2004-04-02 2004-04-02
US60121604P 2004-08-12 2004-08-12
US60122904P 2004-08-12 2004-08-12
PCT/US2005/011332 WO2005097195A2 (en) 2004-04-02 2005-04-01 Methods of reducing aggregation of il-1ra
EP05733155.5A EP1729810B1 (en) 2004-04-02 2005-04-01 Methods of reducing aggregation of il-1ra

Publications (1)

Publication Number Publication Date
PL1729810T3 true PL1729810T3 (pl) 2019-02-28

Family

ID=34964860

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05733155T PL1729810T3 (pl) 2004-04-02 2005-04-01 Sposoby agregacji IL-1ra

Country Status (17)

Country Link
US (3) US10765747B2 (pl)
EP (1) EP1729810B1 (pl)
JP (3) JP2007531738A (pl)
AU (1) AU2005231822B2 (pl)
CA (1) CA2557910C (pl)
CY (1) CY1120831T1 (pl)
DK (1) DK1729810T3 (pl)
ES (1) ES2694252T3 (pl)
HR (1) HRP20181848T1 (pl)
HU (1) HUE040595T2 (pl)
LT (1) LT1729810T (pl)
PL (1) PL1729810T3 (pl)
PT (1) PT1729810T (pl)
RS (1) RS57852B1 (pl)
SI (1) SI1729810T1 (pl)
TR (1) TR201816556T4 (pl)
WO (1) WO2005097195A2 (pl)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2557785A1 (en) * 2004-03-09 2005-10-06 Merck & Co. Inc. Hiv integrase inhibitors
JP2007531738A (ja) * 2004-04-02 2007-11-08 アムジエン・インコーポレーテツド ＩＬ−１ｒａの凝集を低下させる方法
EP2187900B1 (en) * 2007-08-16 2016-11-09 The Schepens Eye Research Institute, Inc. Therapeutic compositions for treatment of inflammation of ocular and adnexal tissues
CN101690801B (zh) * 2009-10-26 2012-08-01 上海交通大学 白细胞介素-1受体拮抗剂的用途及其药物组合物
US8853150B2 (en) 2010-07-29 2014-10-07 Eleven Biotherapeutics, Inc. Chimeric IL-1 receptor type I antagonists
BR112013020195B1 (pt) 2011-02-11 2020-01-07 Swedish Orphan Biovitrum Ab (Publ) Composição farmacêutica livre de citrato compreendendo anakinra e uso de anakinra
ES2600616T3 (es) 2011-03-14 2017-02-10 Phlogo Aps Antagonistas del receptor de la interleucina-1
CN104066439A (zh) * 2011-07-29 2014-09-24 十一生物治疗股份有限公司 纯化的蛋白质
HUE052908T2 (hu) 2012-06-08 2021-05-28 Alkermes Pharma Ireland Ltd Cirkuláris permutációval módosított, agonista és antagonista ligandumok
AU2014243839B2 (en) 2013-03-13 2019-01-03 Buzzard Pharmaceuticals AB Chimeric cytokine formulations for ocular delivery
WO2014193821A1 (en) * 2013-05-28 2014-12-04 Momenta Pharmaceuticals, Inc. Pharmaceutical compositions comprising pyrophosphate
JP6769994B2 (ja) * 2015-04-28 2020-10-14 スウェディッシュ オーファン バイオビトラム アクティエボラーグ （ペーウーベーエル） アナキンラを含む組成物
KR20190088561A (ko) * 2016-12-07 2019-07-26 유니버시티 오브 플로리다 리서치 파운데이션, 인코포레이티드 인터류킨-1 수용체 길항제(IL-1RA) cDNA

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4226846A (en) * 1977-04-01 1980-10-07 New England Nuclear Corporation Albumin microaggregates for radioactive scanning of reticuloendothelial systems
EP0569687B1 (en) * 1984-05-18 2002-08-21 New England Medical Center Hospitals, Inc. Human IL-1 cDNA sequences encoding biologically-active human IL-1 proteins
US4935343A (en) * 1986-08-08 1990-06-19 Syntex (U.S.A.) Inc. Monoclonal antibodies for interleukin-1β
US5359032A (en) 1987-08-26 1994-10-25 Biogen Inc. Interkeukin-1 inhibitor
WO1989004838A1 (en) 1987-11-25 1989-06-01 Immunex Corporation Interleukin-1 receptors
US5296592A (en) 1987-11-25 1994-03-22 Immunex Corporation Process for purifying interleukin-1 receptors
US5319071A (en) * 1987-11-25 1994-06-07 Immunex Corporation Soluble interleukin-1 receptors
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
US6511665B1 (en) * 1987-11-25 2003-01-28 Immunex Corporation Antibodies to interleukin-1 receptors
US5081228A (en) * 1988-02-25 1992-01-14 Immunex Corporation Interleukin-1 receptors
US5075222A (en) * 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
CA2010321C (en) * 1989-02-21 2004-04-06 Thomas F. Tedder Lymphocyte-associated cell surface protein
ES2103305T3 (es) 1989-11-29 1997-09-16 Amgen Boulder Inc Produccion de inhibidor de interleuquina-1 humana recombinada.
WO1992011359A1 (en) 1990-12-20 1992-07-09 University Of Pittsburgh Of The Commonwealth System Of Higher Education A truncated interleukin-1 receptor gene for the treatment of arthritis
US5591457A (en) * 1992-02-07 1997-01-07 Vasogen Inc Method of inhibiting the aggregation of blood platelets and stimulating the immune systems of a human
US5980954A (en) * 1992-02-07 1999-11-09 Vasogen Ireland Limited Treatment of autoimmune diseases
RO113528B1 (ro) 1992-09-17 1998-08-28 Synergen Inc Compozitie farmaceutica pentru inhibarea interleukinei-1
US6242417B1 (en) * 1994-03-08 2001-06-05 Somatogen, Inc. Stabilized compositions containing hemoglobin
US5756466A (en) * 1994-06-17 1998-05-26 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
US5580856A (en) * 1994-07-15 1996-12-03 Prestrelski; Steven J. Formulation of a reconstituted protein, and method and kit for the production thereof
PE64396A1 (es) 1995-01-23 1997-01-28 Hoffmann La Roche Proteina accesoria del receptor de la interleucina 1
US6096728A (en) * 1996-02-09 2000-08-01 Amgen Inc. Composition and method for treating inflammatory diseases
KR20040010739A (ko) 1996-02-09 2004-01-31 암젠 인코포레이티드 인터루킨-1 수용체 길항물질을 포함하는 융합 단백질 및 이를 포함하는 제약학적 조성물
US6416753B1 (en) * 1996-03-15 2002-07-09 The General Hospital Corporation Method for modulating apoptosis
WO1998008969A1 (en) 1996-08-26 1998-03-05 Human Genome Sciences, Inc. Soluble interleukin-1 receptor accessory molecule
US5780431A (en) 1996-09-20 1998-07-14 Neurobiological Technologies, Inc. Pharmaceutical formulations of corticotropin releasing factor having improved stability in liquid form
US6054559A (en) 1997-01-28 2000-04-25 Smithkline Beecham Corporation Interleukin-1 receptor antagonist beta (IL-1raβ)
US6294170B1 (en) 1997-08-08 2001-09-25 Amgen Inc. Composition and method for treating inflammatory diseases
US6541623B1 (en) 1998-04-03 2003-04-01 Hyseq, Inc. Interleukin—1 receptor antagonist and uses thereof
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
AU2915801A (en) 1999-09-07 2001-05-10 Colorado State University Research Foundation In vivo treatment of joint disease using interleukin-1 receptor antagonists
WO2001019390A1 (en) 1999-09-14 2001-03-22 Pfizer Products Inc. Combination treatment with il-1ra and diaryl sulphonyl urea compounds
US6323311B1 (en) * 1999-09-22 2001-11-27 University Of Utah Research Foundation Synthesis of insulin derivatives
CA2477857C (en) 1999-10-04 2012-04-10 Chiron Corporation Stabilized liquid polypeptide-containing pharmaceutical compositions
US7087224B2 (en) 2000-10-31 2006-08-08 Amgen Inc. Method of treating anemia by administering IL-1ra
HUP0400698A3 (en) 2001-02-06 2006-01-30 Merck Patent Gmbh Modified interleukin-1 receptor antagonist (il-1ra) with reduced immunogenicity
US7572770B2 (en) * 2002-06-27 2009-08-11 University Of Zurich Use of an interleukin 1 receptor antagonist and/or pyrrolidinedithiocarbamate for the treatment or prophylaxis of type 2 diabetes
WO2004022718A2 (en) 2002-09-06 2004-03-18 Amgen, Inc. Therapeutic human anti-il-1r1 monoclonal antibody
DK2236154T3 (en) * 2003-02-10 2018-06-25 Biogen Ma Inc IMMUNOGLOBULIN INFORMATION AND METHOD OF PREPARING IT
WO2005019259A2 (en) * 2003-08-25 2005-03-03 Compugen Ltd. Variants of interleukin-1 receptor antagonist: compositions and uses thereof
JP2007531738A (ja) * 2004-04-02 2007-11-08 アムジエン・インコーポレーテツド ＩＬ−１ｒａの凝集を低下させる方法

Also Published As

Publication number Publication date
HUE040595T2 (hu) 2019-03-28
JP6041843B2 (ja) 2016-12-14
LT1729810T (lt) 2018-11-26
AU2005231822B2 (en) 2011-07-21
EP1729810B1 (en) 2018-08-15
HRP20181848T1 (hr) 2018-12-28
CA2557910A1 (en) 2005-10-20
US7619066B2 (en) 2009-11-17
SI1729810T1 (sl) 2018-12-31
US20210121571A1 (en) 2021-04-29
RS57852B1 (sr) 2018-12-31
WO2005097195A3 (en) 2006-08-03
JP6181375B2 (ja) 2017-08-16
CY1120831T1 (el) 2019-12-11
PT1729810T (pt) 2018-11-22
US20070098684A9 (en) 2007-05-03
JP2013136588A (ja) 2013-07-11
DK1729810T3 (en) 2018-12-03
US20050282752A1 (en) 2005-12-22
JP2015078195A (ja) 2015-04-23
TR201816556T4 (tr) 2018-11-21
ES2694252T3 (es) 2018-12-19
CA2557910C (en) 2012-05-29
AU2005231822A1 (en) 2005-10-20
JP2007531738A (ja) 2007-11-08
EP1729810A2 (en) 2006-12-13
US20050271618A1 (en) 2005-12-08
US10765747B2 (en) 2020-09-08
WO2005097195A2 (en) 2005-10-20

Similar Documents

Publication Publication Date Title
HRP20181848T1 (hr) Postupci smanjenja agregacije il-1ra
ME02245B (me) Anti-cd38 humana antitjela i njihove upotrebe
HK1159500A1 (en) Methods for purifying trans-(-)-delta9-tetrahydrocannabinol and trans-()- delta9-tetrahydrocannabinol -(-)-9--()-9-
SI2511297T1 (sl) Proti -CD38 humana protitelesa in njihova uporaba
IL176958A0 (en) Compounds and methods of use
EP1769402A4 (en) ECOSYSTEM PROCESS FOR AGGREGATING AND SEARCHING AND RELATED TECHNIQUES
PL1802579T3 (pl) Pochodne 3-aryloaminopirydynowe
SG117621A1 (en) Methods for enhancing the formation of nickel mono-silicide by reducing the formation of nickel di-silicide
ZA200606319B (en) Anti-CD38 human antibodies and uses therefor
EP1812451A4 (en) COMPOUNDS AND METHODS OF USE THEREOF
IL181507A0 (en) Methods for making retinoids and uses thereof
PL2215908T3 (pl) 2-alkilo-cykloalk(en)ylo-karboksamidy i ich zastosowanie jako fungicydów
EP1737565A4 (en) COS CLAUS CONFIGURATIONS AND METHODS
GB0428291D0 (en) Methods of regenerating NOx-Absorbent
IL178683A0 (en) Methods of diminishing co-abuse potenitial
PL372911A1 (pl) Mieszanina witaminowa
ZA200610295B (en) Anti-IL-13 antibodies, crystals of anti-IL-13 antibodies and complexes comprising them
GB2444371B (en) Fuctionalised interface refreshing
GB0428347D0 (en) Oedema reduction
GB0411417D0 (en) Magic method
GB0308410D0 (en) Cell aggregation
AU2004905174A0 (en) Method of shopping
GB0406358D0 (en) Aircraft personal audio interface